Magenta Therapeutics News Releases https://investor.magentatx.com/ Magenta Therapeutics News Releases en Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-present-40th-annual-goldman-sachs-global CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2019-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Goldman Thu, 06 Jun 2019 16:05:00 -0400 Magenta Therapeutics News Releases 7061 Magenta Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-reports-first-quarter-2019-financial -- Dosed first subjects in Phase 1 study of MGTA-145 first-line mobilization therapy -- -- Presented updated Phase 2 clinical data on MGTA-456 cell therapy in patients with inherited metabolic disorders at American Academy of Neurology annual meeting -- -- Presented preclinical data on E478 stem Thu, 09 May 2019 08:00:00 -0400 Magenta Therapeutics News Releases 7031 Magenta Therapeutics Presents Updated Phase 2 Clinical Data on MGTA-456 Cell Therapy at American Academy of Neurology Annual Meeting https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-presents-updated-phase-2-clinical-data-mgta -- Six-month follow-up on patients with cerebral adrenoleukodystrophy (cALD) shows stable neurological function scores and early and persistent resolution of brain inflammation on MRI -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage Thu, 09 May 2019 07:30:00 -0400 Magenta Therapeutics News Releases 7026 Magenta Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-announces-closing-public-offering-common CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2019-- Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the closing of its previously announced public Mon, 06 May 2019 16:05:00 -0400 Magenta Therapeutics News Releases 7016 Magenta Therapeutics Announces Pricing of Public Offering https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-announces-pricing-public-offering CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2019-- Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced the pricing of its public offering of 4,250,000 shares Wed, 01 May 2019 20:11:00 -0400 Magenta Therapeutics News Releases 7001 Magenta Therapeutics Launches Proposed Public Offering https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-launches-proposed-public-offering CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has launched a proposed public offering of Mon, 29 Apr 2019 16:32:00 -0400 Magenta Therapeutics News Releases 6996 Magenta Therapeutics to Present Preclinical Data on E478 Stem Cell Gene Therapy Expansion Program at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-present-preclinical-data-e478-stem-cell -- Developing novel methods to expand gene-modified stem cells to achieve higher cell doses -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell Mon, 29 Apr 2019 08:00:00 -0400 Magenta Therapeutics News Releases 6986 Magenta Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-announces-first-subjects-dosed-phase-1 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 24, 2019-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that it has dosed the first subjects in a Phase 1 study of Wed, 24 Apr 2019 08:30:00 -0400 Magenta Therapeutics News Releases 6971 Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-reports-fourth-quarter-and-full-year-2018 -- Declared development candidate in first targeted conditioning program -- -- Phase 1 study for first-line stem cell mobilization program to begin 1H19 -- -- Presented updated clinical data for MGTA-456 cell therapy showing signs of early benefit in patients with inherited metabolic disorders Tue, 19 Mar 2019 07:30:00 -0400 Magenta Therapeutics News Releases 6931 Magenta Therapeutics to Present at Investor Conferences in March https://investor.magentatx.com/news-releases/news-release-details/magenta-therapeutics-present-investor-conferences-march CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2019-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the following Wed, 06 Mar 2019 16:05:00 -0500 Magenta Therapeutics News Releases 6916